Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T17:01:24.045Z.
Calculation as of: 2026-10-06T17:01:24.045Z.
Quote observation: 2026-10-06T17:00:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
BridgeBio Oncology Therapeutics Inc.
Market Cap
$284.38M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$286.40M
Free Cash Flow Yield
N/A
TTM Avg
2.65%
3Y Avg
2.65%
5Y Avg
2.65%
Market Cap
$282.68M
Free Cash Flow Yield
N/A
TTM Avg
1.78%
3Y Avg
1.78%
5Y Avg
1.78%
Market Cap
$286.50M
Free Cash Flow Yield
N/A
TTM Avg
41.16%
3Y Avg
41.16%
5Y Avg
41.16%
Market Cap
$287.37M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$288.35M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$277.05M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$293.47M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $284.38M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.40M | N/A | 2.65% | 2.65% | 2.65% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.68M | N/A | 1.78% | 1.78% | 1.78% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $286.50M | N/A | 41.16% | 41.16% | 41.16% |
| Sagimet Biosciences Inc. (SGMT)vs › | $287.37M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $288.35M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $279.36M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.05M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $293.47M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $273.33M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
